Horizon Pharma PLC (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced that it has completed its acquisition ofCrealta Holdings LLC for approximately $510 million in cash. (Original Source)

Shares of Horizon Pharma closed yesterday at $17.45. HZNP has a 1-year high of $39.49 and a 1-year low of $12.86. The stock’s 50-day moving average is $20.67 and its 200-day moving average is $25.31.

On the ratings front, Horizon has been the subject of a number of recent research reports. In a report released yesterday, Brean Murray Carret analyst Difei Yang reiterated a Buy rating on HZNP, with a price target of $32, which represents a potential upside of 83.4% from where the stock is currently trading. Separately, on January 6, Citigroup’s Liav Abraham downgraded the stock to Hold and has a price target of $25.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Difei Yang and Liav Abraham have a total average return of -18.6% and 17.7% respectively. Yang has a success rate of 18.0% and is ranked #3553 out of 3585 analysts, while Abraham has a success rate of 70.6% and is ranked #215.

Overall, one research analyst has rated the stock with a Sell rating, one research analyst has assigned a Hold rating and 8 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $36.50 which is 109.2% above where the stock closed yesterday.

Horizon Pharma PLC is a specialty pharmaceutical company. The Company’s product portfolio consists of ACTIMMUNE, DUEXIS, PENNSAID 2% and RAYOS/LODOTRA, which addresses the unmet therapeutic needs in arthritis, pain, inflammatory and/or orphan diseases.